文献速递肾移植慢性肾脏病肾血管病与高血压

晚期同种异体肾移植丢失与当代心肾代谢治疗

Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.
PubMed 文献 · J Am Soc Nephrol · 2025-04-07

本综述总结晚期肾移植丢失的两大机制:功能恶化导致死亡删失性移植丢失和带功能死亡,各约占晚期丢失的50%。文章讨论SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂、GLP-1受体激动剂及双重内皮素-血管紧张素受体拮抗剂等心肾代谢药物在肾移植人群中的潜在作用。

要点

  • 晚期肾移植丢失中死亡删失性移植丢失与带功能死亡各约占50%。
  • 死亡删失性移植丢失由免疫和非免疫事件共同导致,常见非特异性终点。
  • 带功能死亡主要死因为心血管事件、恶性肿瘤和感染。

核心结论

  • 晚期肾移植丢失由死亡删失性移植丢失和带功能死亡构成,各约占50%,新型心肾代谢药物可能通过抗炎和抗纤维化等机制改善两类结局。

研究设计与样本

  • 本综述总结晚期肾移植丢失主要机制的现有文献,并讨论新型心肾代谢药物在肾移植人群中的潜在作用。

主要发现

  • 死亡删失性移植丢失通常由免疫和非免疫事件组合导致,共同表现为肾小管萎缩、间质纤维化和肾小球硬化等非特异性终点。
  • 带功能死亡的主要原因为心血管事件、恶性肿瘤和感染。
  • SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂、GLP-1受体激动剂及双重内皮素-血管紧张素受体拮抗剂等心肾代谢药物在肾移植人群中尚未充分研究。

关键数值与推荐

  • 晚期肾移植丢失中死亡删失性移植丢失和带功能死亡各约占50%。

临床怎么用

  • 识别晚期移植功能障碍高风险患者,并考虑新型心肾代谢药物在降低心血管事件、感染、恶性肿瘤及抗炎抗纤维化方面的潜在获益。

局限性

  • 新型心肾代谢药物在肾移植受者中尚未充分研究,其潜在获益多基于一般人群证据和外推机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Late kidney allograft loss occurs through one of two mechanisms: ( 1 ) deterioration of kidney function leading to retransplantation or dialysis (death-censored graft loss) and ( 2 ) premature death with a normally functioning transplant (death with graft function)-each accounting for approximately 50% of late kidney graft losses. Late death-censored graft loss typically results from a combination of immune and nonimmune events leading to common nonspecific end points ( e.g ., tubular atrophy, interstitial fibrosis, and glomerulosclerosis). Conversely, leading causes of death with graft function typically include cardiovascular events, malignancy, and infection. With an improved understanding of the multiple mechanism by which late graft dysfunction develops, there is an opportunity to identify patients at greatest risk and institute novel strategies to quell the process. Newer cardiometabolic agents with proven benefit in the general population have not been well-studied in kidney transplant recipients. However, in addition to their potential benefits in reducing cardiovascular, infectious, and malignancy end points (thus minimizing death with graft function risk), many novel agents may have additional anti-inflammatory and/or antifibrotic benefit (minimizing death-censored graft loss risk) in the kidney transplant population. In this review, we summarize existing literature regarding major causes of death-censored graft loss and death with graft function and discuss the potential roles of new cardiorenal metabolic agents including sodium-glucose cotransport 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide 1 receptor agonists, and dual endothelin and angiotensin receptor antagonists in the kidney transplant population, including potential mechanisms to improve death with graft function and death-censored graft loss outcomes.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vinson AJ, Matas A. Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies. J Am Soc Nephrol. 2025. PMID: 40193211. doi:10.1681/ASN.0000000726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。